Skip to main content
Download PDF

Effect of intrabronchial administration of autologous adipose-derived mesenchymal stem cells on severe equine asthma

Stem Cell Research & Therapy volume 13, Article number: 23 (2022) Cite this article

Abstract

Background

Severe equine asthma (SEA) is a common chronic respiratory disease and a significant health and well-being problem in horses. Current therapeutic strategies improve pulmonary function and clinical signs in some horses, but in the long-term, return to full athletic function appears to be rare. The aim of this study was to assess the safety and the effect of intrabronchial administration of adipose-derived mesenchymal stem cells (AD-MSC) on pulmonary inflammatory and clinical parameters in horses with SEA.

Methods

This was a randomized controlled trial. Twenty adult horses diagnosed with SEA were randomly divided into two groups (n = 10), and treated either with a single intrabronchial application of autologous AD-MSC or oral dexamethasone for three weeks. A targeted clinical examination with determination of clinical score, maximal change in pleural pressure during the breathing cycle, and an endoscopic examination of the airways were performed at baseline and three weeks after treatment. Bronchoalveolar lavage fluid was analyzed cytologically, and IL-1β, IL-4, IL-8, IL-17, TNFα and IFNγ mRNA and protein concentrations were measured at baseline and three weeks. The horses were then monitored over one year for recurrence of SEA. A non-inferiority analysis and a linear mixed-effects model were performed to assess differences between treatments.

Results

The non-inferiority of AD-MSC treatment was not established. However, AD-MSC administration significantly ameliorated the clinical score (P = 0.01), decreased the expression of IL-17 mRNA (P = 0.05) and IL-1β (P ≤ 0.001), IL-4 (P ≤ 0.001), TNFα (P = 0.02) protein levels, and had a positive long-term effect on SEA-associated clinical signs (P = 0.02).

Conclusions

Intrabronchial administration of AD-MSC had limited short-term anti-inflammatory effects but improved the clinical signs of SEA at one year.

Background

Severe equine asthma (SEA) is a common chronic respiratory disease of recurrent nature that poses a substantial well-being problem in horses [1,2,3,4,5]. Similar asthma-like conditions occur in humans [4, 6] and cats [7, 8]. Cardinal clinical features are attributed to airway hyperreactivity (AHR) and the underlying inflammatory response of the airways, which is characterized by neutrophilic influx, mucus accumulation, and reversible airway obstruction and remodeling [1, 9]. Traditionally, the management of SEA has included the implementation of changes that reduce exposure to airborne inflammatory stimuli in the equine environment and treatment with topical or systemic anti-inflammatory drugs and bronchodilators [1]. Current therapeutic strategies successfully alleviate clinical signs, but do not adequately treat airway wall remodeling [1, 2, 9,10,11]. Treatment with systemic corticosteroids may also be associated with adverse effects [12,13,14,15]. Inhalation treatment with corticosteroids, for which no significant side effects have been reported, has become a widely used and effective treatment for controlling the clinical signs of SEA [1, 2, 9, 16]. Nevertheless, regardless of the treatment protocol, the majority of treated horses continue to experience episodes of SEA, and approximately half of them remain athletically impaired after disease exacerbation [3].

Regenerative cell-based therapy is becoming an increasingly important treatment option for a variety of clinical problems [17, 18]. Mesenchymal stem cells (MSC), which are undifferentiated cells that can self-renew and transform into tissue cells with specialized functions, are present in the adult organism and are easily obtainable [19]. Therapeutic capabilities of MSC are primarily attributed to immunomodulatory properties that influence the recipient's immune system [20]. Numerous recent studies have investigated the influence of MSC on lung tissue and the lung immune system in animals and humans [21,22,23,24]. It has been shown that treatment with MSC alters the local immune response in induced or naturally acquired lung diseases in mouse models [25,26,27,28,29], dogs [30], cats [31] and a sheep model [32, 33]. So far, only one study in horses with SEA has attempted regenerative therapy using intratracheal injection of autologous bone marrow-derived mononuclear cells (BMMC) rather than MSC. A significant improvement in respiratory effort and reduction in inflammation manifest with reduced neutrophilia and IL-10 levels was reported in horses treated with BMMC [34].

The traditional management of SEA only temporarily controls disease exacerbations in most, but not all, horses [5, 35]. Based on the data available to date, it was considered plausible that MSC treatment could have a positive effect without significant side effects. Therefore, the aim of this study was to investigate the effects of intrabronchial administration of MSC derived from autologous adipose tissue (AD-MSC) in horses with SEA. We hypothesized that intrapulmonary treatment with autologous AD-MSC would have a beneficial immunomodulatory effect and induce durable improvement of clinical signs in horses with SEA.

Materials and methods

This was a randomized controlled trial. All participants in this study were blinded from knowing which treatment horses received. A dedicated study administrator was assigned to manage the study protocol (treatments) and was not linked to any other study procedures. The direct study participants were unblinded after all clinical and laboratory experiments had been completed and the data for statistical analysis had been collected. The unblinding of horse owners/trainers took place after the information on the long term effects of the treatment was obtained.

Animals

Twenty mature horses (median age 15.2, range from 8 to 23 years), representing seven different breeds (four Quarter Horses, two Lipizzaners, two Icelandic horses, two Shetland ponies, one Italian trotter, one Argentine horse, and eight mix-breeds), were included in this study. The study inclusion criteria were signs of asthma exacerbation following antigen challenge, and reversal of airway obstruction with removal of antigen.

Outline of the experimental protocol

All horses included in the study were clinical patients with a documented history of SEA. The horses were included in the study with the written consent of their owners. All owners were familiarized with the study protocol and possible adverse effects of the treatments before giving their consent.

During their participation in the study, all horses were kept in the same research facility under uniform conditions. To aggravate and maintain SEA, moldy, dusty hay was shaken in front of the horses twice a day. The maximal change in pleural pressure during the breathing cycle (ΔPplmax) was measured, and after reversible bronchoconstriction was detected, adipose tissue from the rump of each horse was harvested. The diagnosis of SEA was based on the horse's medical history and clinical examination, including the clinical SEA score, absence of hematological alterations, measurements of ΔPplmax, endoscopy of the airways and cytologic evaluation of bronchoalveolar lavage fluid (BALf). Cytokine (IL-1β, IL-4, IL-8, IL-17, TNFα, IFNγ) expression and concentrations in BALf samples were also measured. The horses were then randomly divided into two groups (n = 10/group) and treated with either MSC (stem cell treatment group: SCT) or dexamethasone (dexamethasone treatment group; DEX). Autologous AD-MSC re-suspended in phosphate buffered saline (PBS, Gibco, USA, cat. no: 14040174) in the SCT group, or placebo (same volume of PBS without AD-MSC) in the DEX group, were injected endoscopically into the lung's right accessory lobe (time 1: T1). Horses with intrabronchial placebo treatment were then treated with dexamethasone mixed into blended grains (Strucomix Original, Cavalor) at an initial dose of 0.165 mg/kg BW PO q24h for three days, then gradually reduced to 0.083 mg/kg BW PO q24h for the following three days, and further to 0.04 mg/kg BW PO q24h for eight days, 0.02 mg/kg BW PO q24h for three days and finally 0.02 mg/kg BW PO q48h for four days [36,37,38]. The horses in the SCT group received an equal amount of blended grains without dexamethasone. The horses were re-evaluated three weeks after starting treatment (time 2: T2) and variables (clinical score, ΔPplmax, endoscopic score, BALf cytology findings, and BALf cytokine expression and concentrations) were again determined.

Clinical scoring

The clinical condition was determined for each animal at T1 and T2, and the information was used to establish a clinical score. Based on a pre-set scale, a clinical score between 0 and 26 was determined for each horse by assessing respiratory rate, nasal discharge, abdominal expiratory lift, nasal flaring, tracheal sounds, bronchial tones, presence of crackles and wheezes, cough reflex, chest resonance, heart rate and rectal temperature. A higher score indicated a more severe clinical disease [39].

Measurement of pleural pressure changes

The ΔPplmax was measured [40,41,42] using an esophageal balloon catheter. The catheter was inserted through the horse's nose, advanced through the ventral nasal passage and introduced into the middle thoracic part of the esophagus. After the balloon was placed at the predetermined location, it was inflated with 20 mL of air. The pressure differences in the balloon were transmitted to a portable detection system Venti Graph (Boehringer Ingelheim Vetmedica; Ingelheim/Boucke GmbH u. Co., Germany). The average ΔPplmax of 10–15 representative breaths was determined. ΔPplmax values of more than five cmH2O were considered as airway obstruction. The esophageal balloon catheter length from the nostrils to the tip of the balloon was recorded for each horse to ensure equal catheter position at T1 and T2.

Once the airway obstruction was confirmed, the horse was treated intravenously with N-butylscopolammonium bromide (Buscopan® compositum, Boehringer Ingelheim, Germany) at a dose of 0.3 mg/kg BW to confirm the reversibility of the obstruction [43].

Adipose tissue collection

The adipose tissue was surgically removed from the subcutaneous fat on the rump. The collection site was clipped, aseptically prepared, and locally anesthetized with 20 mL of 2% lidocaine (Xylocaine, AstraZeneca, UK). Approximately three to four grams of well-vascularized adipose tissue was excised. The samples were collected in sterile containers with 15 mL of pre-cooled transport Dulbecco – modified eagle medium (DMEM, Gibco, USA, cat. no: 21885108) and immediately transported to the laboratory.

Isolation and culture of AD-MSC

The adipose tissue was washed with PBS and minced finely with the scalpel. The adipose tissue was digested in 0.1% type II collagenase (Sigma—Aldrich, DE, cat. no: C1764) overnight at 37 °C with shaking. The digested tissue was then centrifuged at 1600 rpm for four minutes. The cell pellets and the undigested adipose tissue were plated in six-well plates (TPP, Switzerland) in a culture medium containing DMEM (Gibco, USA) and 10% fetal bovine serum (FBS, VWR, USA, cat. no: 97068–085). The cells were cultured at 37 °C in saturated humidity and 5% CO2. The cell culture medium was changed every two to three days. The cells were cultured up to the second or third passage until they had multiplied to 100 million cells. They were then harvested, washed at least three times with PBS, and counted using an automatic image-based cell counter (CytoSMART cell counter, Corning Incorporated, Netherlands). The suspension containing 100 million cells was centrifuged and the pellet was resuspended in 30 mL of PBS and transferred to a sterile 60 mL cloaked syringe. There are no established protocols for intrabronchial administration of MSC in horses. Therefore, in this study, 100 million autologous AD-MSC, diluted in 30 mL of PBS, were administered through the catheter (inserted through the endoscope's working channel) into the right accessory lobe of the horse lung.

An aliquot of the cells was maintained in culture to demonstrate the multi-lineage differentiation potential of MSC. Adipogenic, osteogenic and chondrogenic differentiation potential was confirmed by induction of cell differentiation to adipose (StemPro Adipogenesis Differentiation Kit, Gibco, USA, cat. No. A1007001), osteocytic (StemPro Osteogenesis Differentiation Kit, Gibco, USA, cat. No. A1007201), and chondrocytic (StemPro Chondrogenesis Differentiation Kit, Gibco, USA, cat. No. A1007101) cell types (Fig. 1).

Fig. 1
figure 1

Multilineage differentiation potential of equine adipose derived (AD)-MSCs. Adipogenic differentiation of equine AD-MSC (a, b); staining of intracytoplasmic lipid droplets with Oil-Red-O and cell nuclei with HE at × 100 (a) and × 200 (b) magnification (scale bar 100 µm). Osteogenic differentiation of equine AD-MSC (c, d); staining of calcium matrix formation with Alizarin Red S at × 40 (c) and × 200 (d) magnification (scale bar 100 µm). Chondrogenic differentiation of equine AD-MSC (e, f); staining of the cartilage matrix with Alcian Blue at × 100 (e) and × 200 (f) magnification (scale bar 100 µm)

Full size image

Endoscopic examination, bronchoalveolar lavage fluid collection, and cytology

Prior to endoscopy of the respiratory tract and collection of BALf samples, the horses received a bronchodilator inhalation (five to six puffs, Ventolin, 100 µg/puff, GSK, UK). They were then sedated with 0.01 mg/kg BW of detomidine (Domidine 10 mg/mL, Dechra Veterinary Products, UK) and 0.02 mg/kg BW of butorphanol (Butomidor® 10 mg/mL, Richterpharma, Austria), which were administered intravenously.

An endoscope (Karl Storz – Endoscope, Karl Storz GmbH & Co, Germany) was inserted through the nostrils and passed through the ventral nasal passage to visualize the upper airways, trachea and main bronchi. The upper airways were anesthetized with 30 mL of 0.4% lidocaine solution before passage into the trachea. The endoscope was advanced to the right accessory lobar bronchus, where the bronchoalveolar lavage (BAL) was performed. Sterile warm (37 °C) saline (500 mL) was infused and immediately aspirated through the endoscope's working channel [44]. The amount and macroscopic appearance of the recovered BALf were recorded and the sample was placed in a sterile specimen cup on ice. Based on a predetermined scale, an endoscopic score between 0 and 15 was obtained for each horse by assessing the presence and degree of airway erythema and edema, secretions, hemorrhagic exudate and cough reflex. A higher score indicated more severe clinical disease [39].

The BALf sample was processed within one hour after collection. The total cell count (TCC) was determined with an automatic veterinary hematology analyzer (scil Vet abc Plus+, Horiba, Poland). BALf aliquots of 200 µL were then centrifuged for six minutes at 600 rpm (~ 40 g) in a cytocentrifuge (Centric 250, Domel, Slovenia) and stained with Giemsa stain. A differential cell count of at least 400 consecutive leukocytes was performed at 600× magnification. Epithelial cells and red blood cells were enumerated separately.

The remaining BALf was centrifuged at 1600 rpm for four minutes, and the supernatant and the cell pellets were quickly frozen with liquid nitrogen and stored at − 80 °C for further analysis.

RNA extraction, reverse transcription and quantitative polymerase chain reaction analysis of IL-1β, IL-4, IL-8, IL-17, TNFα, and IFNγ

The total RNA of BALf cell pellets was extracted with Trizol (TRIzol™Reagent, Thermo Fisher Scientific, USA, cat. no: 15596026) according to the manufacturer's protocol. For each sample, the extracted total RNA concentration and purity were measured with a UV spectrophotometer (NanoDrop™ Lite Spectrophotometer).

A reverse transcription-quantitative polymerase chain reaction was performed on all BALf cell pellet samples. Initially, two µg of total RNA of each sample was reverse transcribed into cDNA using a cDNA reverse transcription kit (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Thermo Fisher Scientific, USA, cat. no: 4368814) according to the manufacturer's protocol. All reactions were performed in a total volume of 20 µL. Each sample contained 100 ng/µL of cDNA. The reverse transcription was performed with a thermal cycler (2720 Thermo Cycler, Applied Biosystems, Thermo Fisher Scientific, USA) under the conditions recommended in the manufacturer's protocol (25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min and finally cooled down to 4 °C) and the samples were stored at -20 °C.

The expression of IL-1β, IL-4, IL-8, IL-17, TNFα, and IFNγ mRNA was measured by quantitative PCR with equine GAPDH used as the reference gene [45]. First, standard curves with serial cDNA dilutions were prepared for each gene of interest and reference gene. The slopes of the regression lines were used to calculate the amplification efficiency for each gene. Relative quantification [46] was carried out using the PCR master mix (TaqMan® Universal Master Mix with UNG, Applied Biosystems, Thermo Fisher Scientific, USA, cat.no: 4440038) and gene expression assays (TaqMan® Gene Expression Assays, Applied Biosystems, Thermo Fisher Scientific, USA, cat.no: 4331182; listed in Additional file 4). The results were analyzed using the Pfaffl method and expressed as the ratio of the gene of interest to the reference gene [47, 48]. The LightCycler 96 (Roche Diagnostics GmbH, Germany) was used for amplification and data collection. The samples were amplified in 96-well plates under the following conditions: 50 °C for 2 min, 95 °C for 10 min, and 40 cycles at 95 °C for 15 s and 60 °C for 60 s. All samples were run in triplicate with individual total volumes of 20 µL using a 20 ng cDNA template. Samples obtained from the same horse before and after therapy were analyzed on the same plate.

Cytokine quantification by enzyme-linked immunosorbent assay

The ELISA was performed using Nori Equine IL -1β, IL -4, IL -8, IL -17, TNFα and IFNγ ELISA kits for BAL samples (Genorise Scientific, USA, cat.no: GR106041-BAL, GR106025-BAL, GR106476-BAL, GR106717-BAL, GR106004-BAL, and GR106017-BAL, respectively) according to the manufacturer's protocols. Lower–upper detection limits were 94–6000, 31–2000, 10–600, 94–6000, 31–2000 and 15–1000 pg/mL for IL-1β, IL-4, IL-8, IL-17, TNFα and IFNγ, respectively. Intra-assay variations were 6% for IL-1β, IL-4, IL-8, IL-17 and TNFα ELISA kits, and 7% for IFNγ ELISA kit. The inter-assay variations were 9% for IL-4, IL-8, IL-17, TNFα and IFNγ ELISA kits, and 11% for IL-1β ELISA kit. Supernatants of BALf samples were used for ELISA assays. Standards with known concentrations were prepared and each sample was transferred to the wells. All samples were analyzed in duplicates. After incubation at room temperature, the plates were washed several times with Assay Buffer, working dilutions of the detection antibodies were added to each well, and the plate was incubated at room temperature. After incubation and washing, Conjugate Solution and Substrate Solution were added and the reaction was stopped with a Stop Solution. According to the manufacturer's instructions, optical density was measured in a microplate reader (SunriseTM, Tecan Trading AG, Switzerland) set at 450 nm with wavelength correction set at 540 nm. A standard curve was generated by plotting the mean absorbance (optical density) for each standard against the concentration (pg/mL) using software to derive a four-parameter polynomial curve-fit.

Long-term outcome

The horses were released from the research facility to their original environment after T2 and observed by their owners/trainers and local veterinarians.

SEA in the horses that participated in this study was related to their original (home) environment. Therefore, the owners were instructed not to make any changes in their husbandry until the completion of the study, which was monitored throughout by the investigators. The study was terminated if the horses re-developed SEA clinical signs or, for horses that did not show SEA clinical signs, at the predetermined end date of the study, as detailed in the "Statistical Analysis" section below.

Statistical analysis

The data are presented as means and standard deviations (SD), and the differences between T1 and T2 are presented as means with corresponding 95% confidence intervals [CI]. The proportion of values above the detection range (DR) in ELISA tests is also reported.

A non-inferiority analysis was performed for the primary efficacy outcome: the difference in ΔPplmax between SCT and DEX groups (with a one-sided 97.5% CI obtained by inverting the t-test for two-samples assuming equal variances). The normality assumption was verified with Shapiro–Wilk test of normality; the assumption of equal variances was evaluated with the Bartlett test for homogeneity of variances. The sample size calculation was based on the assumption that ΔPplmax was similar in both treatment groups. To obtain a statistical power of 80% with a two-sided α = 0.025, ten patients per group were required to determine the non-inferiority of SCT compared to DEX, with a margin of non-inferiority of ≤ 7 cmH2O assuming that the SD of differences (end of treatment—baseline) was five in both groups. The non-inferiority margin was determined based on the results reported in Picandet et al. (2003) [49].

The differences between the two treatments were estimated using linear mixed effect models (LME), including random intercept by the horse's ID to account for multiple measurements within the same individual or Tobit (censored) random effect regression models (TRM) for the outcomes with values below DR. Randomization was taken into account by including time and treatment interaction in the model, assuming that the two groups were not different at baseline. Where necessary, the data were log-transformed (using natural logarithms) to meet the assumption of normality. LMEs and TRMs were fitted using the R packages nlme [50] and censReg [51], respectively. All p-values were adjusted for multiple comparisons using the Benjamini and Hochberg method [52] to control the false discovery rate.

Event history analysis was carried out by setting the study's end date at 26th October, 2020. The interval between the end of the treatment protocol, and either the end of the study or the date when clinical signs of asthma reappeared, was calculated for each horse, with the number of days until the end of the study treated as right censored observations. The Kaplan–Meier method was used to estimate the proportion of horses that did not experience a new asthma episode. A log-rank test was used to compare the two treatments.

All analyses were performed with R [53]. The survival analysis was performed with CRAN—Package survival [54]. Adjusted p-values of less than 0.05 were considered statistically significant.

Results

All horses included in the study completed the study protocol. The SCT group included four mares and six geldings (three Quarter horses, two Lipizzaners, two Icelandic horses, three mix-breeds) with a mean age of 15.5 (3.9) years. The DEX group included seven mares and three geldings (one Quarter horse, two Shetland ponies, one Italian trotter, one Argentine horse, and five mix-breeds) with a mean age of 14.9 (2.9) years.

All horses developed pathognomonic clinical signs after the initial antigen challenge (increased respiratory rate, severe cough, flared nostrils, serous nasal discharge, marked and forced exhalation), which persisted until the start of treatment. Auscultation of the trachea and chest revealed crackles and wheezing. Bacterial or fungal infections were ruled out by BAL cytological evaluation. Reversibility of airway obstruction was confirmed in all horses. No adverse effects were observed in the SCT group during the treatment period. In the DEX group, slight pulsation of the digital arteries and/or warmer hooves on palpation were noted in seven horses during the first few days after starting treatment; however, none of the horses showed discomfort or lameness associated with DEX. The increased pulsation subsided spontaneously after a few days.

Clinical variables and the cytology of BALf

Non-inferiority of SCT in terms of ΔPplmax was not established: ΔPplmax decreased by 9.3 (5.8) cmH2O in DEX and by 1.6 (5.4) cmH2O in SCT groups (P = 0.9, upper bound of one-sided 97.5% CI 13.1).

The clinical score decreased by a value of 3.4 [− 5.464; − 1.303] (Padj = 0.01) in the SCT group. The score decreased by an additional 3.1 [− 5.889; − 0.277] points in the DEX group, which, after adjusting for multiple comparisons, was not significantly different from that of SCT (Padj = 0.1). The endoscopic score remained unchanged over time in SCT while it decreased in DEX, but this was not significantly different from SCT (Table 1).

Table 1 Clinical score and endoscopic score
Full size table

The mean TCC of the BALf did not differ significantly over time in SCT. Also, the mean TCC did not differ between treatments. Similar results were obtained in the differential leukocyte counts (Table 2).

Table 2 Bronchoalveolar lavage fluid cytology
Full size table

Relative quantification of the mRNA and protein concentration of cytokines

The mRNA quantification was successful for all cytokines, whereas the detection of cytokine proteins (by ELISA) was successful only for IL-1β, IL-4 and TNFα. Other cytokine concentrations were below the DR of the respective ELISA tests. The mRNA ratio of most cytokines remained stable over time in SCT and DEX while that of IL-17 decreased over time in SCT (Padj = 0.05). The mRNA ratio of IL-17 also decreased in DEX, which was not significantly different from SCT (Padj = 0.2), (Table 3).

Table 3 Relative quantification of cytokines' mRNA and their protein concentration
Full size table

The concentration of the cytokines IL-1β (Padj = 0.001), IL-4 (Padj = 0.001) and TNFα (Padj = 0.02) decreased significantly in SCT. A decrease in IL-1β, IL-4 and TNFα concentrations was also observed in DEX, which did not differ significantly from SCT (Table 3).

Long-term outcome

In the follow-up phase it took longer until horses treated with MSC had an exacerbation of SEA. Exacerbations of SEA were documented in the DEX group shortly after discontinuation of treatment, while most horses in the SCT group remained stable for at least 300 days after discontinuation of SCT (P = 0.02) (Fig. 2).

Fig. 2
figure 2

Long-term outcome. The timepoint expressed in number of days after completion of treatment when horses re-developed signs of SEA and required treatment. SCT, Stem cell treatment; DEX, Dexamethasone treatment; p value

Full size image

Discussion

In this study, the intrabronchial application of autologous AD-MSC had a modest short-term therapeutic effect and a possible positive long-term effect on SEA. Short-term effects were expressed in a reduction of the CS score, a reduced expression of IL-17 and reduced concentrations of IL-1β, IL-4 and TNFα in BALf. Several other variables showed a tendency to improve in the SCT group, which was similar to DEX treatment. The long-term effect of MSC observed in our study is consistent with the results of Trzil et al. (2016), who reported reduced AHR and airway remodeling, and a reduction in inflammation nine months after starting therapy in cats [31]. Treatment with BMMC may also have a positive immunomodulatory effect in SEA, as reported in a small group of horses [34].

In our study, AD-MSC were used. Adipose tissue- and bone marrow-derived MSC have a similar surface immunophenotype and differentiation potential [55,56,57] and appear to be similarly effective on fibrosis-promoting pathways [30]. The anti-inflammatory effect of MSC is achieved through the regulation of Th1 and Th2 cytokines [23], mainly through their induction of CD4 regulatory T cells (Treg) [24,25,26]. MSC also manipulate their environment through paracrine actions, which directly promotes cell and tissue repair [24, 58, 59]. Adipose-derived MSCs were classified based on adhesion to plastic, morphology, and trilineage differentiation [60]. Equine AD-MSC, cultured in basal growth medium, adhered to the bottom of plastic culture dishes and showed typical fibroblast-like morphology. Since no specific data or guidelines for the determination of surface markers of equine MSCs have been published to date, this was not pursued in this study.

Intrabronchial administration of biological drugs allows direct access to and more rapid interaction with the immune system of the lungs. Compared to systemic therapy, fewer cells are required and the possibility of potentially harmful systemic side effects of treatment is lower [21]. Therefore, AD-MSC were administered intrabronchially in this study. To investigate the effect of MSC therapy on SEA-related pulmonary inflammation, MSC treatment was compared with dexamethasone treatment. Constant antigenic challenge promotes neutrophil accumulation in the airways of SEA affected horses [1, 2], leading to upregulation of several inflammatory pathways and the production of pro-inflammatory cytokines [61,62,63,64,65,66,67]. The pathogenic process of SEA operates via positive feedback loops that promote persistent inflammation [62]. Dexamethasone has an immunosuppressive effect that inhibits the activation of the positive feedback loops [68,69,70]. Therefore, DEX serves as an appropriate control to study the effect of SCT.

The expression of pro-inflammatory cytokines (IL-1β, IL-8 and TNFα) and cytokine representatives of the immune responses of type 1 (Th1: IFNγ), type 2 (Th2: IL -4) and type 17 (Th17: IL-17) were investigated to assess different pathways of the immune response. The study design required that the horses remain in an exacerbated SEA state while AD-MSC were cultured. Therefore, cytokine expression in this study was the reflection of a steady-state SEA. This is most likely the reason why at the time of sampling the cytokines IL-4, IL-17 and IFNγ, which are crucial especially in the initial phase of inflammation [65, 66, 71], were somehow lower compared to other cytokines.

Stem cell treatments in other studies also showed variable results in terms of cytokine gene expression and translation, but consistently demonstrated a reduction in airway inflammation and parenchymal damage [22,23,24]. Cho et al. (2014) reported a reduction of inflammation and symptoms in the mouse asthma model following intravenous administration of AD-MSC. The treatment inhibited the expression of Th2 cytokines and increased the expression of Th1 cytokines in BALf [27]. Similar results were reported by Mariñas-Pardo et al. (2014) after intravenous administration of labeled AD-MSC rapidly downregulated airway inflammation associated with Th1 cytokines. It is important to note that MSC treatment effects decreased under sustained allergen challenge, although MSC were still present in the lungs 72 h and two weeks after administration [28]. Other similar studies have shown that MSC are short-lived and cannot be detected 24 h after infusion [72, 73], although even after phagocytosed by macrophages, they are thought to continue to modulate the adaptive immune response [73]. Thus, the therapeutic effect of MSC is most likely not related to their viability in local tissues. Intrabronchial delivery of biologic therapeutics is also considered advantageous over systemic delivery, as fewer cells are required and potential adverse systemic side effects of treatment are reduced [21]. It also allows direct access to and faster interaction with the local pulmonary immune system. These were the reasons for choosing intrabronchial MSC administration in this study.

The pathophysiology of inflammatory processes in SEA is not fully understood. An interaction of Th1, Th2 and Th17 differentiation pathways has been proposed to play a crucial role in a chronic asthma model [1, 2, 74,75,76]. In this study, IL-1β, TNFα and IL-8 mRNA was readily detected in all horses at T1. Treatment with MSC influenced the expression of IL-17, a pro-inflammatory cytokine that plays a crucial role in triggering inflammatory responses, including autoimmune diseases. The exact role and underlying mechanism of dysregulated production of IL-17 and the inflammation triggered by IL-17 are still not well understood [77]. It is important to note that TNFα and IL-1β are, among some other cytokines, the downstream target genes of IL-17 [78], which may also be the reason for a decrease in TNFα and IL-1β concentrations in BALf. We could not pinpoint the reason for the attenuation of the transcription of IL-17 mRNA in this study. It was reported that microRNA (miRNA) expression strongly influences the concentrations of IL-17 [79]. Stem cell treatment may cause differential expression of miRNA, which may affect the transcription of IL-17 mRNA [79, 80]. IL-17 is most likely a critical cytokine that combines T cell activation with the mobilization of neutrophils [81] and indirectly promotes their chemotaxis and activation [35]. The decreased expression of IL-17 may have significantly contributed to the improvement of CS and the long-term positive effect of MSC treatment. The effect of dexamethasone treatment on IL-17 expression was even more evident; however, the immunomodulatory pathways of both treatments are different [82].

It was not possible to define how MSC treatment affected mRNA stability and translation as well as the post-transcriptional stability of cytokines. The mRNA translation was only detected for IL-1β, IL-4 and TNFα, all of which were significantly decreased in BALf in SCT. IL-1β synthesis is controlled both at the transcriptional and post-transcriptional or translational levels [83, 84]. Based on our results, IL-1β levels were most likely reflective of reduced mRNA translation or post-translational attenuation of the protein, since the IL-1β mRNA remained stable from T1 to T2. The same would also apply to IL-4. Relatively low values of IL-4 mRNA and high concentrations of IL-4 in BALf do not agree with the data of other researchers who reported a good correlation between the mRNA and the amount of IL-4 protein secretion in biological samples [85]. The presence of IL-4 in human samples indicates a predominance of a Th2 immune response [86, 87]. The Th2 immune response further modulates the mRNA stability in a positive feedback loop [85, 88, 89]. This could explain the low stability of IL-4 mRNA in the asthmatic lung of horses since the pathogenesis of the disease is different and Th2 polarization is not predominant in horses. Low levels of IL-4 mRNA can still produce high levels of protein because multiple molecules of protein are translated from each mRNA molecule [90].

TNFα mRNA [91,92,93] and protein [91, 92] have short half-lives and low stability in systemic circulation and biological samples. Therefore the high levels of both in our samples were surprising. These results differ from the results of Montgomery et al. [2018), who found low values of the TNFα protein in the respiratory tract of asthmatic horses [94]. The regulatory mechanisms controlling the synthesis of TNFα at the post-transcriptional level depend on cell types and cell activation pathways [95, 96]. In general, macrophage activation stimulates the translation of TNFα, which is otherwise blocked, resulting in high TNFα levels [96]. It appears that MSC treatment may affect the post-transcriptional and translational phases of TNFα gene expression.

The mRNA expression was not always associated with detectable concentrations of cytokine proteins (by ELISA) in this study. Differences in detection can be attributed to the variable stability of mRNAs. This is a known characteristic when biological samples are analyzed by both methods [97,98,99]. Most studies report a strong association between IFNγ mRNAs and the protein concentration and a more variable association between TNFα and IL-8 mRNAs and their proteins. Expression of mRNA and protein concentration also have limited correlation for IL-1β, IL-4 and IL-17 [98]. Other regulatory mechanisms may influence cytokine gene expression, some of which are related to post-transcriptional regulation and the silencing of mRNAs by miRNAs, as discussed above [79].

The undetectable values (value below the ELISA detection range) of the IL-8 protein in BALf were surprising. IL-8 gene expression is often markedly increased in BALf samples from asthmatic horses [66, 100, 101]. The reasons for this may be attributed to the post-transcriptional, pre-, and post-translational control of the transcript. IL-8 mRNA is very stable in biological samples [93, 102]; however, it has been reported that the IL-8 protein has relatively short stability in plasma and probably also in BALf [103]. In addition, IL-8 receptors are densely expressed on neutrophils [104, 105], which are extremely prevalent in the inflammatory environment of the asthmatic lungs of horses. The IL-8 protein probably binds neutrophils shortly after mRNA translation and may therefore no longer be detectably by ELISA [104]. It is also possible that the IL-8 translation was attenuated by miRNA-17 [106], which may be abundant in asthma [107].

The long-term effect of treatments was determined based on the redevelopment of pathognomonic clinical signs for SEA. The use of diagnostic modalities used in T1 and T2 for long-term follow-up would likely provide some additional information. However, such a study model would require a population-based approach with a more representative number of participants to account for non-standardized investigation time-points, husbandry conditions and animal use protocols.

In this study, we did not evaluate the lung tissue after treatment; therefore, any structural changes and remodeling of lung tissue could not be determined. Repeated lung biopsies were not within the scope of this study and would likely trigger inflammatory pathways unrelated to SEA.

Conclusions

This study has identified several positive effects of MSC treatment in SEA. Some changes were captured by assessment after a short-term, but most pronounced was the long-term effect on SEA, which was strikingly different for horses in the SCT compared to the DEX group. It is important to note, however, that SCT did not preclude recurrence of the clinical signs of SEA in all horses at one year. Like several other studies concerning regenerative therapy, we could not define the exact effects of MSC treatment on the development and persistence of asthma. The results of this study suggest that positive effects of treatment with MSC on SEA are possible and that the horse may be a suitable model to thoroughly investigate the effects of MSC treatment in asthma and possibly other chronic diseases.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

AD-MSC:

Adipose-derived mesenchymal stem cells

AHR:

Airway hyperreactivity

BAL:

Bronchoalveolar lavage

BALf:

Bronchoalveolar lavage fluid

BMMC:

Bone marrow-derived mononuclear cells

BW:

Body weight

CD4:

Cluster of differentiation 4

CI:

Confidence interval

CS:

Clinical score

cDNA:

Complementary deoxyribonucleic acid

DEX:

Dexamethasone treatment group

DMEM:

Dulbecco – modified eagle medium

DR:

Detection range

ELISA:

Enzyme-linked immunosorbent assay

ES:

Endoscopic score

FBS:

Fetal bovine serum

GAPDH:

Glyceraldheyde 3-phosphate dehydrogenase

IFNγ:

Interferon gamma

IL:

Interleukine

LME:

Linear mixed effects

MSC:

Mesenchymal stem cells

PBS:

Phosphate buffered saline

qPCR:

Quantitative polymerase chain reaction

ΔPplmax :

Maximum change in pleural pressure during the respiratory cycle

PO:

Per os treatment

RNA:

Ribonucleic acid

mRNA:

Messenger RNA

miRNA:

Micro-RNA

RT-qPCR:

Reverse transcription-quantitative polymerase chain reaction

SD:

Standard deviation

SEA:

Severe equine asthma

SCT:

Stem cell treatment group

TCC:

Total cell count

Th:

T-helper cells

TNFα:

Tumor necrosis factor alpha

Treg:

Regulatory T cells

TRM:

Tobit random effect regression model

T1:

Time 1, beginning of treatment

T2:

Time 2, end of treatment

References

  1. Robinson NE. International workshop on equine chronic airway disease. Michigan State University 16–18 June 2000. Equine Vet J. 2001;33(1):5–19.

    Article  CAS  PubMed  Google Scholar 

  2. Lavoie JP. Recurrent airway obstruction (heaves) and summer-pasture-associated obstructive pulmonary disease. In: McGorum BC, Dixon PM, Robinson NE, Schumacher J, editors: Equine Respiratory Medicine and Surgery. Saunders Elsevier; Amsterdam 2007. p. 565–589.

  3. Aviza G, Ainsworth D, Eicker S, Santiago M, Divers T, Perkins G. Outcome of horses diagnosed with and treated for heaves (recurrent airway obstruction). Equine Vet Educ. 2001;13:243–6.

    Article  Google Scholar 

  4. Leclere M, Lavoie-Lamoureux A, Lavoie JP. Heaves, an asthma-like disease of horses. Respirology. 2011;16(7):1027–46.

    Article  PubMed  Google Scholar 

  5. Couëtil LL, Cardwell JM, Leguillette R, Mazan M, Richard E, Bienzle D, et al. Equine asthma: current understanding and future directions. Front Vet Sci. 2020;7:450.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68(12):1520–31.

    Article  CAS  PubMed  Google Scholar 

  7. Corcoran BM, Foster DJ, Fuentes VL. Feline asthma syndrome: a retrospective study of the clinical presentation in 29 cats. J Small Anim Pract. 1995;36(11):481–8.

    Article  CAS  PubMed  Google Scholar 

  8. Trzil JE. Feline asthma: Diagnostic and treatment update. Vet Clin North Am Small Anim Pract. 2020;50(2):375–91.

    Article  PubMed  Google Scholar 

  9. Couëtil LL, Cardwell JM, Gerber V, Lavoie JP, Léguillette R, Richard EA. Inflammatory airway disease of horses—revised consensus statement. J Vet Intern Med. 2016;30(2):503–15.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Leclere M, Lavoie-Lamoureux A, Joubert P, Relave F, Setlakwe EL, Beauchamp G, et al. Corticosteroids and antigen avoidance decrease airway smooth muscle mass in an equine asthma model. Am J Respir Cell Mol Biol. 2012;47(5):589–96.

    Article  CAS  PubMed  Google Scholar 

  11. Bullone M, Vargas A, Elce Y, Martin JG, Lavoie JP. Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma. Sci Rep. 2017;7:8843.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Cuming RS, Groover ES, Wooldridge AA, Caldwell FJ. Review of glucocorticoid therapy in horses. Part 1: pharmacology. Equine Vet Educ. 2018;30(3):141–50.

    Article  Google Scholar 

  13. Eyre P, Elmes P, Stickland S. Corticosteroid-potentiated vascular responses of the equine digit: a possible pharmacologic basis for laminitis. Am J Vet Res. 1979;40(1):135–8.

    CAS  PubMed  Google Scholar 

  14. Cohen N, Carter G. Steroid hepatopathy in a horse with glucocorticoid-induced hyperadrenocorticism. J Am Vet Med Assoc. 1992;200(11):1682–4.

    CAS  PubMed  Google Scholar 

  15. Mair TS. Bacterial pneumonia associated with corticosteroid therapy in three horses. Vet Rec. 1996;138(9):205–7.

    Article  CAS  PubMed  Google Scholar 

  16. Pereira MM, Groover E, Wooldridge A, Caldwell F. Review of glucocorticoid therapy in horses. Part 2: clinical use of systemic glucocorticoids in horses. Equine Vet Educ. 2018;30(4):213–24.

    Article  Google Scholar 

  17. Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med. 2009;13(11–12):4385–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Voga M, Adamic N, Vengust M, Majdic G. Stem cells in veterinary medicine—current state and treatment options. Front Vet Sci. 2020;7:278.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL. Identification of a lineage of multipotent hematopoietic progenitors. Development. 1997;124(10):1929–39.

    Article  CAS  PubMed  Google Scholar 

  20. Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells. 2019;8(8):784.

    Article  CAS  PubMed Central  Google Scholar 

  21. Fujita Y, Kadota T, Araya J, Ochiya T, Kuwano K. Clinical application of mesenchymal stem cell-derived extracellular vesicle-based therapeutics for inflammatory lung diseases. J Clin Med. 2018;7(10):255.

    Article  CAS  Google Scholar 

  22. Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. Stem Cells Int. 2019;2019:4236973.

    PubMed  PubMed Central  Google Scholar 

  23. Zhang LB, He M. Effect of mesenchymal stromal (stem) cell (MSC) transplantation in asthmatic animal models: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2019;54:39–52.

    Article  PubMed  CAS  Google Scholar 

  24. Yen BL, Yen M, Wang L, Liu K, Sytwu H. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Stem Cells Transl Med. 2020;9(10):1163–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bonfield TL, Koloze M, Lennon DP, Zuchowski B, Yang SE, Caplan AI. Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. Am J Physiol Lung Cell Mol Physiol. 2010;299(6):L760–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lee SH, Jang AS, Kwon JH, Park SK, Won JH, Park CS. Mesenchymal stem cell transfer suppresses airway remodeling in a toluene diisocyanate-induced murine asthma model. Allergy Asthma Immunol Res. 2011;3(3):205–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cho KS, Park MK, Kang SA, Park HY, Hong SL, Park HK, et al. Adipose-derived stem cells ameliorate allergic airway inflammation by inducing regulatory T cells in a mouse model of asthma. Mediators Inflamm. 2014;2014:436476.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Mariñas-Pardo L, Mirones I, Amor-Carro O, Fraga-Iriso R, Lema-Costa B, Cubillo I, et al. Mesenchymal stem cells regulate airway contractile tissue remodeling in murine experimental asthma. Allergy. 2014;69(6):730–40.

    Article  PubMed  CAS  Google Scholar 

  29. Abreu SC, Antunes MA, Xisto DG, Cruz FF, Branco VC, Bandeira E, et al. Bone marrow, adipose, and lung tissue-derived murine mesenchymal stromal cells release different mediators and differentially affect airway and lung parenchyma in experimental asthma. Stem Cells Transl Med. 2017;6(6):1557–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hao Y, Ran Y, Lu B, Li J, Zhang J, Feng C, et al. Therapeutic effects of human umbilical cord-derived mesenchymal stem cells on canine radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 2018;102(2):407–16.

    Article  PubMed  Google Scholar 

  31. Trzil JE, Masseau I, Webb TL, Chang C-H, Dodam JR, Liu H, et al. Intravenous adipose-derived mesenchymal stem cell therapy for the treatment of feline asthma: a pilot study. J Feline Med Surg. 2016;18(12):981–90.

    Article  PubMed  Google Scholar 

  32. Ihara K, Fukuda S, Enkhtaivan B, Trujillo R, Perez-Bello D, Nelson C, et al. Adipose-derived stem cells attenuate pulmonary microvascular hyperpermeability after smoke inhalation. PloS ONE. 2017;12(10):e0185937.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Cardenes N, Aranda-Valderrama P, Carney JP, Sellares Torres J, Alvarez D, Kocydirim E, et al. Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model. BMJ Open Respir Res. 2019;6(1):e000308.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Barussi FCM, Bastos FZ, Leite LMB, Fragoso FYI, Senegaglia AC, Brofman PRS, et al. Intratracheal therapy with autologous bone marrow-derived mononuclear cells reduces airway inflammation in horses with recurrent airway obstruction. Respir Physiol Neurobiol. 2016;232:35–42.

    Article  CAS  PubMed  Google Scholar 

  35. Murcia RY, Vargas A, Lavoie J-P. The interleukin-17 induced activation and increased survival of equine neutrophils is insensitive to glucocorticoids. PLoS ONE. 2016;11(5):e0154755.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Cornelisse CJ, Robinson NE, Berney CEA, Kobe CA, Boruta DT, Derksen FJ. Efficacy of oral and intravenous dexamethasone in horses with recurrent airway obstruction. Equine Vet J. 2004;36(5):426–30.

    Article  CAS  PubMed  Google Scholar 

  37. DeLuca L, Erb HN, Young JC, Perkins GA, Ainsworth DM. The effect of adding oral dexamethasone to feed alterations on the airway cell inflammatory gene expression in stabled horses affected with recurrent airway obstruction. J Vet Intern Med. 2008;22(2):427–35.

    Article  CAS  PubMed  Google Scholar 

  38. Ainsworth DM, Cheetham J. Disorders of the respiratory system. In: Reed S, Bayly W, Sellon D, editors. Equine internal medicine. 3rd ed. New York: Elsevier Saunders; 2010. p. 290–371.

    Google Scholar 

  39. Beeler-Marfisi J, Clark ME, Wen X, Sears W, Huber L, Ackerley C, et al. Experimental induction of recurrent airway obstruction with inhaled fungal spores, lipopolysaccharide, and silica microspheres in horses. Am J Vet Res. 2010;71(6):682–9.

    Article  PubMed  Google Scholar 

  40. Willoughby RA, McDonell WN. Pulmonary function testing in horses. Vet Clin North Am Large Anim Pract. 1979;1(1):171–96.

    Article  CAS  PubMed  Google Scholar 

  41. Klein HJ, Deegen E. The measurement of interpleural pressure - a method to assess lung mechanics in the horse. 1987;4(3):141–7

  42. Hoffman AM. Clinical application of pulmonary function testing in horses. In: Lekeux P, editor. Equine respiratory diseases. 2002. https://www.ivis.org/library/equine-respiratory-diseases/clinical-application-of-pulmonary-function-testing-horses. Accessed 14 Feb 2021.

  43. Couëtil LL, Hammer J, Feutz MM, Nogradi N, Perez-Moreno C, Ivester K. Effects of N-butylscopolammonium bromide on lung function in horses with recurrent airway obstruction. J Vet Intern Med. 2012;26(6):1433–8.

    Article  PubMed  Google Scholar 

  44. Hoffman AM. Bronchoalveolar lavage: sampling technique and guidelines for cytologic preparation and interpretation. Vet Clin North Am Equine Pract. 2008;24(2):423–35.

    Article  PubMed  Google Scholar 

  45. Beekman L, Tohver T, Dardari R, Léguillette R. Evaluation of suitable reference genes for gene expression studies in bronchoalveolar lavage cells from horses with inflammatory airway disease. BMC Mol Biol. 2011;12(1):5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Giguère S, Prescott JF. Quantitation of equine cytokine mRNA expression by reverse transcription-competitive polymerase chain reaction. Vet Immunol Immunopathol. 1999;67(1):1–15.

    Article  PubMed  Google Scholar 

  47. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Forlenza M, Kaiser T, Savelkoul HFJ, Wiegertjes GF. The use of real-time quantitative PCR for the analysis of cytokine mRNA levels. In: De Ley M, editor. Cytokine protocols; methods in molecular biology, vol. 820. Berlin: Springer; 2012. p. 7–23.

    Chapter  Google Scholar 

  49. Picandet V, Léguillette R, Lavoie JP. Comparison of efficacy and tolerability of isoflupredone and dexamethasone in the treatment of horses affected with recurrent airway obstruction ('heaves’). Equine Vet J. 2003;35(4):419–24.

    Article  CAS  PubMed  Google Scholar 

  50. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1–144. 2020. Available from: https://CRAN.R-project.org/package=nlme. Accessed 5 Nov 2020

  51. Henningsen A. censReg: Censored Regression (Tobit) Models. R package version 0.5–32. 2020. Available from: https://cran.r-project.org/web/packages/censReg/censReg.pdf. Accessed 5 Nov 2020

  52. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.

    Google Scholar 

  53. R Core Team. R version 3.6.3. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. Available from: https://www.eea.europa.eu/data-and-maps/indicators/oxygen-consuming-substances-in-rivers/r-development-core-team-2006. Accessed 5 Nov 2020

  54. Therneau T. A package for survival analysis in S. version 2.38. 2015. Available from: https://mran.microsoft.com/snapshot/2017-02-04/web/packages/survival/citation.html. Accessed 5 Nov 2020

  55. Russell KA, Chow NHC, Dukoff D, Gibson TWG, LaMarre J, Betts DH, et al. Characterization and immunomodulatory effects of canine adipose tissue- and bone marrow-derived mesenchymal stromal cells. PLoS ONE. 2016;11(12):e0167442.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Bearden RN, Huggins SS, Cummings KJ, Smith R, Gregory CA, Saunders WB. In-vitro characterization of canine multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study. Stem Cell Res Ther. 2017;8(1):218.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Sasaki A, Mizuno M, Ozeki N, Katano H, Otabe K, Tsuji K, et al. Canine mesenchymal stem cells from synovium have a higher chondrogenic potential than those from infrapatellar fat pad, adipose tissue, and bone marrow. PLoS ONE. 2018;13(8):e020922.

    Article  CAS  Google Scholar 

  58. Tang GN, Li CL, Yao Y, Xu ZB, Deng MX, Wang SY, et al. MicroRNAs involved in asthma after mesenchymal stem cells treatment. Stem Cells Dev. 2016;25(12):883–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Du YM, Zhuansun YX, Chen R, Lin L, Lin Y, Li JG. Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma. Exp Cell Res. 2018;363(1):114–20.

    Article  CAS  PubMed  Google Scholar 

  60. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.

    Article  CAS  PubMed  Google Scholar 

  61. Holcombe SJ, Jackson C, Gerber V, Jefcoat A, Berney C, Eberhardt S, et al. Stabling is associated with airway inflammation in young Arabian horses. Equine Vet J. 2010;33(3):244–9.

    Article  Google Scholar 

  62. Robinson NE. Recurrent airway obstruction (Heaves). In: Lekeux P, editor: Equine Respiratory Diseases; IVIS; 2001. Available from: http://www.ivis.org/special_books/Lekeux/robinson/reference.asp. Accessed 17 Mar 2000

  63. Giguère S, Viel L, Lee E, MacKay RJ, Hernandez J, Franchini M. Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate. Vet Immunol Immunopathol. 2002;85(3):147–58.

    Article  PubMed  Google Scholar 

  64. Ainsworth DM, Grünig G, Matychak MB, Young J, Wagner B, Erb HN, et al. Recurrent airway obstruction (RAO) in horses is characterized by IFN-γ and IL-8 production in bronchoalveolar lavage cells. Vet Immunol Immunopathol. 2003;96(1):83–91.

    Article  CAS  PubMed  Google Scholar 

  65. Debrue M, Hamilton E, Joubert P, Lajoie-Kadoch S, Lavoie JP. Chronic exacerbation of equine heaves is associated with an increased expression of interleukin-17 mRNA in bronchoalveolar lavage cells. Vet Immunol Immunopathol. 2005;105(1):25–31.

    Article  CAS  PubMed  Google Scholar 

  66. Padoan E, Ferraresso S, Pegolo S, Castagnaro M, Barnini C, Bargelloni L. Real time RT-PCR analysis of inflammatory mediator expression in recurrent airway obstruction-affected horses. Vet Immunol Immunopathol. 2013;156(3):190–9.

    Article  CAS  PubMed  Google Scholar 

  67. Bullone M, Murcia RY, Lavoie J-P. Environmental heat and airborne pollen concentration are associated with increased asthma severity in horses. Equine Vet J. 2016;48(4):479–84.

    Article  CAS  PubMed  Google Scholar 

  68. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286–90.

    Article  CAS  PubMed  Google Scholar 

  69. Barnes PJ. Nuclear factor-kappa B. Int J Biochem Cell Biol. 1997;29(6):867–70.

    Article  CAS  PubMed  Google Scholar 

  70. van der Velden VH. Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm. 1998;7(4):229–37.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Zamorano J, Rivas MD, Pérez-G M. Interleukin-4: a multifunctional cytokine. Inmunologia. 2003;22(2):215–24.

    Google Scholar 

  72. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;3:297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells Dayt Ohio. 2018;36(4):602–15.

    Article  CAS  Google Scholar 

  74. Horohov DW, Beadle RE, Mouch S, Pourciau SS. Temporal regulation of cytokine mRNA expression in equine recurrent airway obstruction. Vet Immunol Immunopathol. 2005;108(1–2):237–45.

    Article  CAS  PubMed  Google Scholar 

  75. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87–113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Bond SL, Hundt J, Léguillette R. Effect of injected dexamethasone on relative cytokine mRNA expression in bronchoalveolar lavage fluid in horses with mild asthma. BMC Vet Res. 2019;15(1):397.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: From discovery to targeting. Trends Mol Med. 2016;22(3):230–41.

    Article  CAS  PubMed  Google Scholar 

  78. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Khan D, Ansar AS. Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs. Front Genet. 2015;6:236.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Park J, Jeong S, Park K, Yang K, Shin S. Expression profile of microRNAs following bone marrow-derived mesenchymal stem cell treatment in lipopolysaccharide-induced acute lung injury. Exp Ther Med. 2018;15(6):5495–502.

    PubMed  PubMed Central  Google Scholar 

  81. Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol. 2015;69(1):142–59.

    Article  Google Scholar 

  82. Alangari AA. Genomic and non-genomic actions of glucocorticoids in asthma. Ann Thorac Med. 2010;5(3):133–9.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Knudsen PJ, Dinarello CA, Strom TB. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol. 1986;137(10):3189–94.

    CAS  PubMed  Google Scholar 

  84. Schindler R, Clark BD, Dinarello CA. Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells. J Biol Chem. 1990;265(18):10232–7.

    Article  CAS  PubMed  Google Scholar 

  85. Dokter WH, Esselink MT, Sierdsema SJ, Halie MR, Vellenga E. Transcriptional and posttranscriptional regulation of the interleukin-4 and interleukin-3 genes in human T cells. Blood. 1993;81(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  86. Wong CK, Ho CY, Ko FWS, Chan CHS, Ho ASS, Hui DSC, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 2001;125(2):177–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Fallon PG, Jolin HE, Smith P, Emson CL, Townsend MJ, Fallon R, et al. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity. 2002;17(1):7–17.

    Article  CAS  PubMed  Google Scholar 

  88. Umland SP, Razac S, Shah H, Kyle Nahrebne D, Egan RW, Motasim BM. Interleukin-5 mRNA stability in human T cells is regulated differently than interleukin-2, interleukin-3, interleukin-4, granulocyte/macrophage colony-stimulating factor, and interferon- γ. Am J Respir Cell Mol Biol. 1998;18(5):631–42.

    Article  CAS  PubMed  Google Scholar 

  89. Yarovinsky TO, Butler NS, Monick MM, Hunninghake GW. Early exposure to IL-4 stabilizes IL-4 mRNA in CD4 + T cells via RNA-binding protein HuR. J Immunol. 2006;177(7):4426–35.

    Article  CAS  PubMed  Google Scholar 

  90. Popescu FD, Popescu F. A review of antisense therapeutic interventions for molecular biological targets in asthma. Biol Targets Ther. 2007;1(3):271–83.

    CAS  Google Scholar 

  91. Ferraiolo BL, Moore JA, Crase D, Gribling P, Wilking H, Baughman RA. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Drug Metab Dispos Biol Fate Chem. 1988;16(2):270–5.

    CAS  PubMed  Google Scholar 

  92. Simó R, Barbosa-Desongles A, Lecube A, Hernandez C, Selva DM. Potential role of tumor necrosis factor-α in downregulating sex hormone–binding globulin. Diabetes. 2012;61(2):372–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Mahmoud L, Al-Enezi F, Al-Saif M, Warsy A, Khabar KS, Hitti EG. Sustained stabilization of interleukin-8 mRNA in human macrophages. RNA Biol. 2014;11(2):124–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Montgomery JB, Husulak ML, Kosolofski H, Dos Santos S, Burgess H, Meachem MD. Tumor necrosis factor-alpha protein concentrations in bronchoalveolar lavage fluid from healthy horses and horses with severe equine asthma. Vet Immunol Immunopathol. 2018;202:70–3.

    Article  CAS  PubMed  Google Scholar 

  95. Clark A. Post-transcriptional regulation of pro-inflammatory gene expression. Arthritis Res Ther. 2000;2(3):172.

    Article  CAS  Google Scholar 

  96. Mijatovic T, Houzet L, Defrance P, Droogmans L, Huez G, Kruys V. Tumor necrosis factor-α mRNA remains unstable and hypoadenylated upon stimulation of macrophages by lipopolysaccharides. Eur J Biochem. 2000;267(19):6004–12.

    Article  CAS  PubMed  Google Scholar 

  97. Maier T, Güell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009;583(24):3966–73.

    Article  CAS  PubMed  Google Scholar 

  98. Shebl FM, Pinto LA, García-Piñeres A, Lempicki R, Williams M, Harro C, et al. Comparison of mRNA and protein measures of cytokines following vaccination with HPV-16 L1 virus like particles. Cancer Epidemiol Biomark Prev. 2010;19(4):978–81.

    Article  CAS  Google Scholar 

  99. Koussounadis A, Langdon SP, Um IH, Harrison DJ, Smith VA. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci Rep. 2015;5(1):10775.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Franchini M, Gill U, von Fellenberg R, Bracher VD. Interleukin-8 concentration and neutrophil chemotactic activity in bronchoalveolar lavage fluid of horses with chronic obstructive pulmonary disease following exposure to hay. Am J Vet Res. 2000;61(11):1369–74.

    Article  CAS  PubMed  Google Scholar 

  101. Hansen S, Otten ND, Birch K, Skovgaard K, Hopster-Iversen C, Fjeldborg J. Bronchoalveolar lavage fluid cytokine, cytology and IgE allergen in horses with equine asthma. Vet Immunol Immunopathol. 2020;220:109976.

    Article  CAS  PubMed  Google Scholar 

  102. Villarete LH, Remick DG. Transcriptional and post-transcriptional regulation of interleukin-8. Am J Pathol. 1996;149(5):1685–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Orlikowsky TW, Neunhoeffer F, Goelz R, Eichner M, Henkel C, Zwirner M, et al. Evaluation of IL-8-concentrations in plasma and lysed EDTA-blood in healthy neonates and those with suspected early onset bacterial infection. Pediatr Res. 2004;56(5):804–9.

    Article  CAS  PubMed  Google Scholar 

  104. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307(1):97–101.

    Article  CAS  PubMed  Google Scholar 

  105. Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593–619.

    Article  CAS  PubMed  Google Scholar 

  106. Oglesby IK, Vencken SF, Agrawal R, Gaughan K, Molloy K, Higgins G, et al. miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production. Eur Respir J. 2015;46(5):1350–60.

    Article  CAS  PubMed  Google Scholar 

  107. Simpson LJ, Patel S, Bhakta NR, Choy DF, Brightbill HD, Ren X, et al. A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production. Nat Immunol. 2014;15(12):1162–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was funded by Slovenian Research Agency Fund MR-05.

Author information

Authors and Affiliations

  1. Veterinary Faculty, University of Ljubljana, 1000, Ljubljana, Slovenia

    Neža Adamič, Sonja Prpar Mihevc, Petra Kramarič, Uroš Krapež, Gregor Majdič & Modest Vengust

  2. Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia

    Rok Blagus

  3. Clinical Studies, University of Guelph, Guelph, ON, Canada

    Laurent Viel

  4. School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Andrew M. Hoffman

  5. Department of Pathobiology, University of Guelph, Guelph, ON, Canada

    Dorothee Bienzle

Authors
  1. Neža Adamič
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonja Prpar Mihevc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rok Blagus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Petra Kramarič
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uroš Krapež
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gregor Majdič
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laurent Viel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrew M. Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dorothee Bienzle
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Modest Vengust
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Hypothesis and experimental design: NA, RB, GM, AH, DB, MV. Conduction of the experiment: NA, SM, PK, UK, LV, DB, MV. Analysis and interpretation: NA, RB, GM, DB, MV. Writing/Revision: All authors. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Modest Vengust.

Ethics declarations

Ethics approval and consent to participate

The study protocol was reviewed by the National ethics committee (Document No. U34401-37/2017/9). All methods were carried out in accordance with relevant guidelines and regulations. Owner informed consent was given for every horse included in this study.

Consent for publication

Not applicable.

Competing interests

GM is partial owner of Animacel ltd. Other authors have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

: Figure S1. Clinical and endoscopic scores. CS, clinical score; ES, endoscopic score; SCT, Stem cell treatment; DEX, Dexamethasone treatment; T1, Beginning of treatment; T2, End of treatment; log, logarithmic transformation.

Additional file 2

: Figure S2. Bronchoalveolar lavage fluid cytology (x109/L). TCC, mean total cell count; Mac, macrophages; Neut, neutrophils; Lymph, lymphocytes; Eos, eosinophils; Mast, mast cells; SCT, Stem cell treatment; DEX, Dexamethasone treatment; T1, Beginning of treatment; T2, End of treatment; log, logarithmic transformation

Additional file 3

: Figure S3. Relative quantification of cytokines' mRNA and their protein concentration. e, ELISA determined concentration of cytokine; IL, Interleukin; SCT, Stem cell treatment; DEX, Dexamethasone treatment; T1, Beginning of treatment; T2, End of treatment; log, logarithmic transformation

Additional file 4

: List of primer sequences used for qRT-PCR

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adamič, N., Prpar Mihevc, S., Blagus, R. et al. Effect of intrabronchial administration of autologous adipose-derived mesenchymal stem cells on severe equine asthma. Stem Cell Res Ther 13, 23 (2022). https://doi.org/10.1186/s13287-022-02704-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13287-022-02704-7

Keywords

Stem Cell Research & Therapy

ISSN: 1757-6512